Life as a GSK HIV CS

[Anonymous]

Metrics, sales, market share change, blackbox warning, lack of data, being forced to have speaker programs, overnights, stress, worry. The reward: if sales are good, you make bonus. If sales drop, you explain why / review metrics and hope that you don't get invited to Dallas. Oh, by the way, nobody gets promoted. Don't believe me? Ask around! http://www.cafepharma.com/ubbthreads/images//graemlins/frown.gif Life as a GSK HIV CS

[Anonymous]

Is this job a promotion from field sales? Do you get a higher base pay?

[Anonymous]

It's a demotion.

[Anonymous]

This division is worse than primary care. I came here thinking this was "Specialty" and found out it is nothing more then glorified pharma with more micromanagement. We are treated like little children. I should have stayed where I was!

[Anonymous]

Don't come here! Too much travel, terrible mgmt, negative environment. Pressure to push worn out products. Hey, others are better and the docs know it too.

[Anonymous]

Thats why I left for Gilead!

[Anonymous]

Management is completely clueless as to the moral of this division...or they simply do care....what a joke they are happy we are above plan yet the fact remains epz. and Lexiva have pathetic national shares given the time they have been on the market. How many of the marketing people have actually carried the bag. I know there are a couple of RSD that have NEVER even sold anything. what a joke

[Anonymous]

Which RSD do you think could sell our line?...and keep up the numbers...and get back in the door (again)? My vote would be SM.

[Anonymous]

2 reps per territory selling the same damn drugs......territories are enormous.....we spend most of the time in the car.........is this what you would call a productive use of time? Who thought of this? Someone with NO business sense!

[Anonymous]

See Forbes.com / business / healthcare article about Gilead. Those with high Combivir MS are in trouble...see you in Dallas!

MP

[Anonymous]

Gilead is gonna kill us! BTW: Hey MP, FU!

[Anonymous]

Mass exodus is occuring.....Tibotec has already taken some of us.......who will be next.

[Anonymous]

Epzicom is about to take off, we will be kickin Gilead in the butt very soon, their reps are worthless and weak

[Anonymous]

[ QUOTE ]
Mass exodus is occuring.....Tibotec has already taken some of us.......who will be next.

[/ QUOTE ]
Shitty products + Shitty culture + Huge territories = ADIOS

[Anonymous]

[ QUOTE ]
Epzicom is about to take off, we will be kickin Gilead in the butt very soon, their reps are worthless and weak

[/ QUOTE ]
You must be kidding me. About to tke off.....this drug has been out for weel over a year....not to mention the components.......you must be in market......idiot.

[Anonymous]

Epzicom and Lexiva are our future! Let go of CBV and TZV! Truvada is flaky! Kaletra and Sustiva don't work. Save for salvage.

Signed, GSK MKting

[Anonymous]

New year is almost here and mp's party in dallas is just around the corner.

[Anonymous]

[ QUOTE ]
New year is almost here and mp's party in dallas is just around the corner.

[/ QUOTE ]
Is this a team-building and morale boosting meeting?

[Anonymous]

degrading. If in the bottom 25% for just one qtr. you attend. Poeple who have never sold teach you about spreadsheets. Complete joke.

[Anonymous]

I am fianlly away from this division after many years of dedicated service. It is appalling that reps are not appreciated, treated as adults, and constantly threatened with nonsense. It is a shame that the ones in charge don't realize that people are not motivated by threats or being treated badly. It is so sad that a formerly good company that treated reps with respect has gone so far down in the treatment of employees. I am so glad to be gone from this lack of organization. The number of speaker programs is crazy and regardless of how many times management is told that they aren't working and people don't turn out, they just continue to insist that this is the way things should be done. Don't ask the reps how something should be done or what would work well in their territories!!!!! We are their eyes and ears but we might as well be deaf. There are no open lines of communication and this division is only "best in the class" in the management minds.
Very sad situation.
Feel blessed to be out of this and on to a better company, with better products.

[Anonymous]

well said......mp and his cronies are dipshits

[Anonymous]

BYE, BYE------Tibotec here I come. I am sooooo excited. Nice compact territory, great management, positive culture........

[Anonymous]

Tibotec is courting me...ya'll gonna be surprised when I leave!

[Anonymous]

I would like to take this opportunity to thank you folks at GSK HIV for spending your valuable time and money to train new reps and groom them for future employment with other HIV companies. Your generosity is second to none and you continue to exhibit a sincere willingness to be a team player in the HIV Community.
Here's wishing you a Happy New Year and the best for 2006!

Good Selling and Happy Recruiting

[Anonymous]

Regional meeting next week! great chance to role play! Make your RSD proud by reviewing all faxbacks, detail aids and have your metrics up to date! I just love this place! BTW: I'm gonna ball JH at midnite! YEOW! If he hollers let him go!

[Anonymous]

The idiots on top don't understand that a robot-like rep does not work in HIV. No wonder everybody wants out.

[Anonymous]

Its a shame that marketing drives the message and the CS is expected to repeat lame-ass lines which causes the physician to lose all respect for us. I mean, really, there's only a little to begin with and the rest is earned only to lose it as a means of keeping the job. Its a damn shame.

[Anonymous]

I agree with the above post. We're not selling...we are repeating taglines.

[Anonymous]

thats what happens when you staff a marketing with people who have never sold anything. How can they expect us to RESPECT them when they have never carried the bag.
M.H. is a fatass.

[Anonymous]

Re: MH poster
Friend, be careful. She is creating metric tables for damn near every conceivable measurable. Be busy / be active / be careful.
Signed: someone who REALLY knows.

[Anonymous]

I belieave the post was refering the Mr. NH is the marketing department. but she is a fat ass too.

[Anonymous]

This divison should be known as the M & M's going forward..............Marlon's Morons.

[Anonymous]

How 'bout Pittman's Pimps

[Anonymous]

What happened to Lewis Waldrep?

[Anonymous]

HELP>>>>>ANYONE KNOW WHEN THE LOSERS CIRCLE TRIP IS THIS YEAR?????? I NEED TO SAVE THE DATE!!!!!!

[Anonymous]

Your competion isn't the other drug companies, it is one another internally, think about it.

[Anonymous]

Study: Gilead's HIV combo beats Glaxo's
By STEVE MITCHELL
UPI Senior Medical Correspondent

WASHINGTON, Jan. 18 (UPI) -- A major study indicates the triple combination of Gilead's Viread and Emtriva with Bristol-Myers Squibb's Sustiva is a better initial treatment for HIV infection and could replace the current gold standard of Sustiva combined with GlaxoSmithKline's Combivir.

The finding, which appears in the Jan. 19 issue of The New England Journal of Medicine, is the first to show that one combination regimen is superior to the other for initial HIV infection treatment. Gilead funded the study.

"It suggests that people who are starting therapy for the first time are going to be better off on the (Viread/Emtriva) regimen," Dr. Joel Gallant, the study's lead author and associate director of the AIDS Service at The Johns Hopkins University School of Medicine, told United Press International.

Gallant, who is a paid consultant to both Gilead and Glaxo, noted that, since the study began, Viread and Emtriva have been combined into one pill called Truvada, "so it's now possible to take this regimen with two pills a day with no food restrictions, so its quite simple."

The regimen could be further simplified to one pill a day as Gilead and BMS are developing a single pill that contains Viread, Emtriva and Sustiva.

"This regimen has really become the gold standard for starting therapy," Gallant said, adding that "the publication of this study will have the effect of reaching doctors who may not have been following this closely and will lead to the movement of this being the standard regimen for people who don't have any complications" on Truvada and Sustiva.

Gilead said the previous release of preliminary data from the study has already led to physicians and patients shifting from Combivir to Truvada.

"Truvada has eclipsed Combivir as the most widely prescribed retroviral," Norbert Bischofberger, Gilead's executive vice president of research and development, told UPI. "This will just further enforce that notion and lend it some momentum."

Gilead and BMS said last week they had data supporting the bioequivalence of the triple combination pill. "We are going to file an NDA with the FDA in the second quarter of this year and this study will further support use of that particular regimen and that particular pill," Bischofberger said. "The timing (of the release of this study) is just perfect," he added.

"The more difficult question is what to do with people who are already on the Combivir regimen and are doing well," Gallant said. He noted that the one-year data indicates the side effect of lipoatrophy, or loss of fat in the face, arms and legs, is a problem and will likely continue to be an issue in long-term follow-up, so that could be a reason for people to switch even if they are doing well.

Glaxo defended Combivir's safety profile and said in a statement that the open-label nature of the study made it difficult to draw conclusions about which regimen was best.

"Results seen with Combivir plus (Sustiva) in this trial were positive and reinforce the value of Combivir demonstrated in previous research," the company said in a statement.

"We are always interested in learning more about existing treatments for HIV, but we realize the limited value of a single, open-label study to make comparisons among products," said Mark Shaefer, Glaxo's acting vice president for HIV clinical research for the infectious diseases medicines development center. "Fortunately, Combivir is one of the most studied HIV therapies on the market with a wealth of information available."

In the study, which is known as Study 934, 517 treatment-naive patients at 67 sites in the United States, Europe and the United Kingdom were randomly assigned to receive either the Viread/Emtriva regimen or the Combivir combo.

At the end of the first year of treatment 80 percent of patients in the Viread/Emtriva group had undetectable levels of HIV compared to 70 percent of the Combivir group. The average increase in CD4 levels in the Viread/Emtriva arm at 190 cells per cubic millimeter of blood was higher than the Combivir arm, which had an average CD4 rebound of 158.

Gallant said one of the reasons the Viread/Emtriva regimen fared better was that more people in the Combivir arm had to drop out due to side effects. Approximately 9 percent of the Combivir group withdrew compared to only 4 percent of the Viread/Emtriva group, with the most common reason being anemia.

Glaxo countered that previous presentations of interim data from this study may account for the higher dropout rate in the Combivir group. "Given the open label nature of this trial, public release of the 24-week results may have contributed to the higher discontinuation rate seen in the arm containing Combivir," the company said.

[Anonymous]

Gilead HIV drug combo beats GSK rival in phase III trial
20th January 2006
By Staff Writer
Recently published data from a phase III HIV trial has shown that patients given Gilead's Viread with Emtriva and Bristol-Myers Squibb's Sustiva achieved superior viral suppression with fewer adverse effects than patients taking Sustiva plus GlaxoSmithKline's Combivir.

AdvertisementThe clinical trial (Study 934) compared a treatment regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Sustiva (efavirenz) to a regimen of Combivir (lamivudine/zidovudine) with Sustiva in treatment-naive patients with HIV.

Data published in the New England Journal of Medicine show that a significantly greater percentage of patients taking a regimen containing Viread and Emtriva achieved and maintained HIV RNA less than 400 copies/mL, with fewer side effects that resulted in study discontinuation, and had a greater increase in CD4 cell counts compared to patients taking a Combivir-based regimen.

For the 48-week primary endpoint of the study, 84% of patients in the Viread/Emtriva arm compared to 73% of patients in the Combivir arm achieved and maintained HIV RNA less than 400 copies/mL through week 48 using the time to loss of virologic response algorithm (TLOVR).

Similarly, 80% of patients in the Viread/Emtriva arm compared to 70% of patients in the Combivir arm achieved and maintained HIV RNA less than 50 copies/mL through week 48 using the TLOVR algorithm.

The 48-week safety analysis, meanwhile, showed that a significantly greater percentage of patients in the Combivir group (9%) experienced adverse events that resulted in the discontinuation of study medications compared to the Viread/Emtriva arm (4%).

Viread and Emtriva are often prescribed together as a fixed-dose combination tablet called Truvada (emtricitabine and tenofovir disoproxil fumarate), which became commercially available after Study 934 began. Both Truvada and Combivir are widely used fixed-dose combination medicines from the nucleoside reverse transcriptase inhibitor (NRTI) class of antiretrovirals. NRTIs are commonly regarded as the 'backbone' of combination therapy for HIV.

"Data like these are important to help define ways for physicians to simplify effective HIV therapy for treatment-naive patients," said Dr Joel Gallant, of the Johns Hopkins University School of Medicine, a lead investigator for the study and lead author of the paper. "Even with the remarkable advances made in the field of HIV medicine in the last 10 years, there is still a need for improved and simplified therapy."

[Anonymous]

Truvada + kidney transplant, a match made in heaven!

[ QUOTE ]
Gilead HIV drug combo beats GSK rival in phase III trial
20th January 2006
By Staff Writer
Recently published data from a phase III HIV trial has shown that patients given Gilead's Viread with Emtriva and Bristol-Myers Squibb's Sustiva achieved superior viral suppression with fewer adverse effects than patients taking Sustiva plus GlaxoSmithKline's Combivir.

AdvertisementThe clinical trial (Study 934) compared a treatment regimen of Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Sustiva (efavirenz) to a regimen of Combivir (lamivudine/zidovudine) with Sustiva in treatment-naive patients with HIV.

Data published in the New England Journal of Medicine show that a significantly greater percentage of patients taking a regimen containing Viread and Emtriva achieved and maintained HIV RNA less than 400 copies/mL, with fewer side effects that resulted in study discontinuation, and had a greater increase in CD4 cell counts compared to patients taking a Combivir-based regimen.

For the 48-week primary endpoint of the study, 84% of patients in the Viread/Emtriva arm compared to 73% of patients in the Combivir arm achieved and maintained HIV RNA less than 400 copies/mL through week 48 using the time to loss of virologic response algorithm (TLOVR).

Similarly, 80% of patients in the Viread/Emtriva arm compared to 70% of patients in the Combivir arm achieved and maintained HIV RNA less than 50 copies/mL through week 48 using the TLOVR algorithm.

The 48-week safety analysis, meanwhile, showed that a significantly greater percentage of patients in the Combivir group (9%) experienced adverse events that resulted in the discontinuation of study medications compared to the Viread/Emtriva arm (4%).

Viread and Emtriva are often prescribed together as a fixed-dose combination tablet called Truvada (emtricitabine and tenofovir disoproxil fumarate), which became commercially available after Study 934 began. Both Truvada and Combivir are widely used fixed-dose combination medicines from the nucleoside reverse transcriptase inhibitor (NRTI) class of antiretrovirals. NRTIs are commonly regarded as the 'backbone' of combination therapy for HIV.

"Data like these are important to help define ways for physicians to simplify effective HIV therapy for treatment-naive patients," said Dr Joel Gallant, of the Johns Hopkins University School of Medicine, a lead investigator for the study and lead author of the paper. "Even with the remarkable advances made in the field of HIV medicine in the last 10 years, there is still a need for improved and simplified therapy."

[/ QUOTE ]

[Anonymous]

Gilead is packing up Truvada with Sustiva, nice combo, as your kidneys blow out you will have bad nightmares - good luck selling that POS!

[Anonymous]

To the last poster: You must be in GSK marketing......You are an idiot......is that you jerry?

[Anonymous]

That dude (gay or gal) must not be getting the same weekly data that the rest of us are.

[Anonymous]

[ QUOTE ]
Gilead is packing up Truvada with Sustiva, nice combo, as your kidneys blow out you will have bad nightmares - good luck selling that POS!

[/ QUOTE ]
Looks like another disgruntled and jealous GSK HIV Rep is hating life. That negativity typifies the GSK HIV Division. So glad I'm gone....YIPPEEE

[Anonymous]

Tibotec seems to be taking alot of time in terms of offers.....How many of you have been waiting over two weeks since the interview with an RVP.......I am SOOO ready to leave.

[Anonymous]

Tibotec is done with us. They cherry picked o few people and then didn't have the stones to let the others know in hopes that GSK will find out who interviewed and make their lives a living hell. Good way to trim the competition. I am certainly ready to discuss POWER 1 and POWER 2 and how poorly they were designed and the "Procrit" rep hasn't tha faintest idea how to sell HIV therapeutics so let them earn each script. Bitter?????you're damn right. Now I am more determined than ever to escape this insanity.....Hey Pete.....CROI was an embarassment....2 posters??old data????? How about those new pens!!!!!!!!!!!!! WOW

[Anonymous]

[ QUOTE ]
Epzicom and Lexiva are our future! Let go of CBV and TZV! Truvada is flaky! Kaletra and Sustiva don't work. Save for salvage.

Signed, GSK MKting

[/ QUOTE ]
I work for one of the drug companies that is mentioned above (am I with Abbott or BMS??) It really doesn't matter. The fact is that I am thrilled that GSK has lost its title of being the leader of HIV therapy. Most of the time, the GSK reps are just plain awful. If it's lack of morale, lack of direction, etc, I don't know. I just know that most of the GSK reps are awful, and most of them ruin it for the rest of us. I know it sounds awful to be happy for the demise of the HIV division because the patients need all the drugs they can get. That being said, I am so happy that they are going on drugs that aren't made by the awful GSK. You have management (example: loser RM in the SF Bay area) that borders on terrorism, crappy product knowledge (does anyone know the buiding blocks of DNA at your company???), and expect to be leaders because you are GSK. There seem to be a handful of good GSK people, but from what I have experienced the last few years, the management, marketing, medical, and sales divisions are the worst in the HIV arena. It is a perverse pleasure to watch the gestapo-run GSK fall. Thank God the patients don't really need GSK products anymore. Combivir, Trizivir, and Epzicom are getting trounced by Gilead, and Lexiva is getting trounced by BMS, Abbott, and even Pfizer, who have almost no reps promoting Viracept. GOOD JOB, GSK!!

[Anonymous]

[ QUOTE ]
Gilead is packing up Truvada with Sustiva, nice combo, as your kidneys blow out you will have bad nightmares - good luck selling that POS!

[/ QUOTE ]
Or you could go on Epzicom and die. At least with Truavda, you can look at creatinie clearance. Epzicom has terrible half-life compared to Truvada, and more hypersensitivity than GSK will admit. I hope Truvada continues to kick Epzicom's butt. Just how many more recyled drugs does GSK plan to roll out? Oh, and great job with fos-amprenavir..what a winner you have there!!! The Truvada-Sustiva combination will make patients happy, as well as the Gilead and BMS reps. Sucks to be GSK!

[Anonymous]

[ QUOTE ]
[ QUOTE ]
Gilead is packing up Truvada with Sustiva, nice combo, as your kidneys blow out you will have bad nightmares - good luck selling that POS!

[/ QUOTE ]
Or you could go on Epzicom and die. At least with Truavda, you can look at creatinie clearance. Epzicom has terrible half-life compared to Truvada, and more hypersensitivity than GSK will admit. I hope Truvada continues to kick Epzicom's butt. Just how many more recyled drugs does GSK plan to roll out? Oh, and great job with fos-amprenavir..what a winner you have there!!! The Truvada-Sustiva combination will make patients happy, as well as the Gilead and BMS reps. Sucks to be GSK!

[/ QUOTE ]
Epzicom and Lexiva will pave the way to a bright GSK future!

[Anonymous]

GSK has really never measured up. Just ask Wall Street! JP is average CEO at best. When a VP of Sales says 10 calls per day and 10 minutes per call....Well! Good Place to gain experience and move on. Company likes Female Reps and DSMs since GSK will pay less. Would not recommend staying beyond 5 years! More into paperwork then sales results. Very poor management period! Lets just say I know! Working for a Biotech Company and yes I am a DSM.

[Anonymous]

We are getting beaten up every day. Our CCR5 was pulled, so the future of GSK virology division is bleak. I wish I could get out, but I can't imegine working for Abbott, BMS, Tibotec, or Gilead. A lot of us are transfering out of HIV into other areas.

[Anonymous]

[ QUOTE ]
We are getting beaten up every day. Our CCR5 was pulled, so the future of GSK virology division is bleak. I wish I could get out, but I can't imegine working for Abbott, BMS, Tibotec, or Gilead. A lot of us are transfering out of HIV into other areas.

[/ QUOTE ]
You obviously don't work here you jerk. GSK does not have a virology division. Get out of here!

[Anonymous]

[ QUOTE ]
[ QUOTE ]
We are getting beaten up every day. Our CCR5 was pulled, so the future of GSK virology division is bleak. I wish I could get out, but I can't imegine working for Abbott, BMS, Tibotec, or Gilead. A lot of us are transfering out of HIV into other areas.

[/ QUOTE ]
You obviously don't work here you jerk. GSK does not have a virology division. Get out of here!

[/ QUOTE ]
Nor could you pay me enough to!!!!!

[Anonymous]

[ QUOTE ]
[ QUOTE ]
We are getting beaten up every day. Our CCR5 was pulled, so the future of GSK virology division is bleak. I wish I could get out, but I can't imegine working for Abbott, BMS, Tibotec, or Gilead. A lot of us are transfering out of HIV into other areas.

[/ QUOTE ]
You obviously don't work here you jerk. GSK does not have a virology division. Get out of here!

[/ QUOTE ]
You are a true idiot. GSK may not call it a virology division, but everyone who sells HIV meds knows it's a virology division, even though we call it HIV CS. Get off the HIV board, you primary care loser piece of trash who can't make the grade into specialty!

[Anonymous]

[ QUOTE ]
[ QUOTE ]
[ QUOTE ]
We are getting beaten up every day. Our CCR5 was pulled, so the future of GSK virology division is bleak. I wish I could get out, but I can't imegine working for Abbott, BMS, Tibotec, or Gilead. A lot of us are transfering out of HIV into other areas.

[/ QUOTE ]
You obviously don't work here you jerk. GSK does not have a virology division. Get out of here!

[/ QUOTE ]
You are a true idiot. GSK may not call it a virology division, but everyone who sells HIV meds knows it's a virology division, even though we call it HIV CS. Get off the HIV board, you primary care loser piece of trash who can't make the grade into specialty!

[/ QUOTE ]
Your cheesy company calls it virology, GSK calls it the "HIV Division". Look at your own business card. Go back to your own board BMS....What is your stock at??????

[Anonymous]

Abbott has a virology division. BMS has a virology division. Roche has a virology division. All of which are far superior to GSK's. You are a true dumbass.

[Anonymous]

[ QUOTE ]
Abbott has a virology division. BMS has a virology division. Roche has a virology division. All of which are far superior to GSK's. You are a true dumbass.

[/ QUOTE ]
You obviously don't work here you jerk. GSK does not have a virology division. Get out of here!

[Anonymous]

[ QUOTE ]
[ QUOTE ]
Abbott has a virology division. BMS has a virology division. Roche has a virology division. All of which are far superior to GSK's. You are a true dumbass.

[/ QUOTE ]
You obviously don't work here you jerk. GSK does not have a virology division. Get out of here!

[/ QUOTE ]
You aren't an HIV rep. Must suck to be stuck in primary care. Whoever you are, obviously you can't make the cut to be specialized. Sucks to be you!

[Anonymous]

Right now, it does suck to be an HIV rep with GSK. I am afraid the good ole days are long gone. Even the docs don't really view us the way they used to, and that is what's even more sad.

[Anonymous]

RM and MPs personal success is so important that they have no remorse paving that road with the flesh and blood of others who have been sacrificed for nothing more than bragging rights. When will someone speak up and not take "the package" that has "gag ordered" so many before. You can't buy everybody for ever. You people at GSK get what you desrve. BAD KARMA HITS HARD AND YOU ARE GETTING NAILED: http://www.cafepharma.com/ubbthreads/images//graemlins/crazy.gif

[Anonymous]

[ QUOTE ]
RM and MPs personal success is so important that they have no remorse paving that road with the flesh and blood of others who have been sacrificed for nothing more than bragging rights. When will someone speak up and not take "the package" that has "gag ordered" so many before. You can't buy everybody for ever. You people at GSK get what you desrve. BAD KARMA HITS HARD AND YOU ARE GETTING NAILED: http://www.cafepharma.com/ubbthreads/images//graemlins/crazy.gif

[/ QUOTE ]
I still want to know why RM still has a job. How many more people is she going to terrorize? I can't begin to count how many reps she has lost over the years. Throw that woman in jail and make her anorexic ass eat. preferably shit.

[Anonymous]

The HIV division is the worst at GSK! It is challenging all right, because the products are shitty. Old drugs repackaged as new. Doctors know it, and don't prescribe them. We have a Nazi as the region head, and too many butt kissing DMs that bow down to him. We are getting our asses kicked by Gilead, BMS, and Abbott. GSK has some decent divisions, but HIV is the bottom of the barrel. 5-10 years ago, it was a different story, though; much better back then. Now it has degenerated into robotic dipshit BS. Whoever posted the above response is obviously not into this division. check the post that is named "Life as an HIV rep at GSK' and you will get the picture even clearer

[Anonymous]

Gilead rep here. Quit your whining; you guys had it good for a long time. Let someone else have the spotlight. Poor GSK HIV waaaaah

[Anonymous]

Yeah, you guys had it good for a long time. Quit being so freaking selfish. GSK had the lion's share until recently, so quit being so greedy and whiny.

[Anonymous]

Yes GSK is big pharma. Get out of that nut house and get with a small biotechnology Oncology Company. It is a wild ride but no micromanagement.

[Anonymous]

A collection of lunatics run the GSK HIV Division, I hear they are insane.

[Anonymous]

[ QUOTE ]
A collection of lunatics run the GSK HIV Division, I hear they are insane.

[/ QUOTE ]
There is seriously something wrong with MP. I am being dead serious. The other one isn't much better. Some of the DM's also seem clearly mentally disturbed, esp. a seriously deranged one out on the west coast (RM)

[Anonymous]

Definitely watch your step around those 2

[Anonymous]

these are good posts. where there's smoke, there's fire. http://www.cafepharma.com/ubbthreads/images//graemlins/confused.gif

[Anonymous]

Life will be better at Tibotech.

[Anonymous]

[ QUOTE ]
Life will be better at Tibotech.

[/ QUOTE ]
Maybe, maybe not. I hear J&J is more anal than GSK.

[Anonymous]

Tibotech appreciates their people and treats them with respect. You obvioulsy aren't in the field and have no clue, everyone knows about your shithole-threatening and demeaning environment. How many professionals from other HIV companies have you recruited? NONE...everyone avoids gsk....PUKE. Go plan your LOSERS CIRCLE you condescending jackass. You people have the worst reputation...you should hear the comments about you jerks, sad. You obviously don't care!

[Anonymous]

[ QUOTE ]
Tibotech appreciates their people and treats them with respect. You obvioulsy aren't in the field and have no clue, everyone knows about your shithole-threatening and demeaning environment. How many professionals from other HIV companies have you recruited? NONE...everyone avoids gsk....PUKE. Go plan your LOSERS CIRCLE you condescending jackass. You people have the worst reputation...you should hear the comments about you jerks, sad. You obviously don't care!

[/ QUOTE ]
Why should I care? I call the shots, peon.

[Anonymous]

You are an idiot

[Anonymous]

we need new people in the field, without all your negative baggage, fresh faces and fresh attitudes will bring epzicom to its rightful place as the #1 prescribed nrti backbone!

[Anonymous]

[ QUOTE ]
we need new people in the field, without all your negative baggage, fresh faces and fresh attitudes will bring epzicom to its rightful place as the #1 prescribed nrti backbone!

[/ QUOTE ]
And YOU need to wake up; it ain't gonna happen. Truvada is the king and Epzicom the lowly dog that bows down to Truvada's feet.

[Anonymous]

[ QUOTE ]
we need new people in the field, without all your negative baggage, fresh faces and fresh attitudes will bring epzicom to its rightful place as the #1 prescribed nrti backbone!

[/ QUOTE ]
This confirms what we hear about your environment at GSK. We value our people unlike you guys. No wonder why everyone wants out.

[Anonymous]

Yeah, morale is really low in the division. Everyone is frustrated and the products are performing poorly. It's just not the same division as it used to be when the products were innovative

[Anonymous]

Whatever happened to Fred Schmid? Where did he go...what happened?

[Anonymous]

This division is dying a slow death

[Anonymous]

Tibotech and Gilead are going to get more of us. The time is drawing near......

[Anonymous]

Last I heard he was with Roche/Trimeris. Sounded like he was pretty happy there.

[Anonymous]

[ QUOTE ]
Last I heard he was with Roche/Trimeris. Sounded like he was pretty happy there.

[/ QUOTE ]
Of course he is happy. He left this loser company, and I am doing the same in 2 weeks. THANK GOD. And RM, MP, you can both kiss my white ass. You too DA.

[Anonymous]

this divison is a complete joke. I've been here long enough to see it fall from grace. Bottom line is that every
thing was great when there was no competition. MP and marketing idiots were not prepared to lead us when the market got crowed with competition. management is laughable. How can they really expect us to trust them. Poor decision after poor decision. Marketing directors with no sales background, sales directors with no sales background, a sales trainer ranked in the bottom 20% and then brought in house to manage the traing program....the list goes on and on. Do you think the really beleave the BS that they are telling us. Not to mention marlon and his circle of yes men and women. Don't give me that bull shit about metrics and 6 calls per day when I am driving 1000 to 1500 miles per week pushing two shit drugs. Who is the dumb son of a bitch that drew up the territory lines. Obviously someone with no sales background who truley understands effectiveness. I absolutely dread this national meeting in AZ. I can here MP now: Hi everyone, welcome to the shit hole Wig Wam.....We tried to get something better in Vegas but the sales just were there.....Anyway I'm sure you would all agree that this is much better than the ariport marriot in dallas.

[Anonymous]

Hey Marlon and Reynolds, you can both kiss my lilly white ass too! You 2 are hated. By like, everyone.

[Anonymous]

Moron..I mean Marlon is hated , but i think Reynolds is hated even more. The competition loves her, though, since she helps their sales.

[Anonymous]

Does anyone know when the next LOSERS CIRCLE with Moron Marlon is? I am sure I will get invited to this one.

[Anonymous]

Why don't people like RM?

[Anonymous]

[ QUOTE ]
Why don't people like RM?

[/ QUOTE ]
Because she is an anorexic psycho skank that has driven turnover in that area as the highest in the nation. For some reason, Moron Marlon keeps her around. Her tactics are notorious in the Bay area by docs and competitive reps, and have been responsible for many headaches. Just look at the shares of Reyataz and Truvada there, and you will see that she actually HELPS the competition. Don't take my word for it; talk to any doc or rep in the Bay area. She is even known in southern California as a legend, but not in a positive light.

[Anonymous]

This division has hit rock bottom. http://www.cafepharma.com/ubbthreads/images//graemlins/mad.gif

[Anonymous]

what about the packing skills? lunches, hair nets etc?
gotta get it all in

[Anonymous]

Anything new on the horizon?

[Anonymous]

[ QUOTE ]
Anything new on the horizon?

[/ QUOTE ]
We have a CCR5 coming. Oh, wait...it was pulled. NOPE, not a damn thing coming, except Moron Marlon and the Losers Circle!

[Anonymous]

[ QUOTE ]
Anything new on the horizon?

[/ QUOTE ]
Truvada rules in SF.

[Anonymous]

Truvada rules everywhere. Epzidog is dying already! And don't get me started on Lexidog! That one died LONG ago.

[Anonymous]

GSK never admits defeat. With these 2, it's time to admit it. We are actually LOSING share with these 2 drugs, and I am sick of it. Docs don't want to use either product

[Anonymous]

GSK = gone from HIV leaders to HIV wannabes

[Anonymous]

I work for a competitor of GSK. It's no wonder you all are performing so poorly. Your reps are NOT professional and because of the behavior of the reps, the stupid selling messages, and the poor style of the management, I am collecting a fat paycheck and fat bonus at the expense of GSK. Life is good! Keep it up, GSK!! I am loving it!

[Anonymous]

I'm sure PDI has some openings on their contract with GSK that you could interview for . . . . . . . . a lot less headaches and BS that you have to put up with compared to GSK HIV! http://www.cafepharma.com/ubbthreads/images//graemlins/wink.gif

[Anonymous]

I want to join another HIV company, and have just interviewed. Wish me luck to get off of this sinking ship!

[Anonymous]

Maybe you could move to SF and work for the revolving door with lovely RM.

[Anonymous]

When is this post going to die?

[Anonymous]

Does anyone know when Marlon the Moron and his sidekick morons are calling the next Losers Circle meeting?

[Anonymous]

if you have to go to that, your days are numbered.

[Anonymous]

Maybe that Gay Cowboy Marlon and his stupid bunch of rodeo dogs like Hannon will leave GSK and allow a real group of professionals to take charge and get charged.

[Anonymous]

I thought Marlon, Nathan, and Mick were the Losers Circle? And the California Princess served them her skank ass for dessert?

[Anonymous]

Mick is no longer leading the PI marketing team. MP and PH have elevated Mick into a RSD job. Now, that's leadership!